Co-delivery of 5-fluorouracil and oxaliplatin in novel poly(3-hydroxybutyrate-co-3-hydroxyvalerate acid)/poly(lactic-co-glycolic acid) nanoparticles for colon cancer therapy.
In the present study, a novel 5FU and OXA co-loaded PHBV/PLGA NPs was developed which induced apoptosis in cancer cells. NPs were prepared by the double emulsion method and their preparation was optimized using D-optimal design of response surface methodology (RSM). 5FU-OXA loaded NPs were evaluated by SEM, DSC and DLS. NPs were spherical as shown by SEM and the results of DSC indicated that both drugs successfully entrapped into NPs. 5FU-OXA loaded NPs exhibited higher cytotoxicity effect than free drugs on cancer cells. For the first time to our knowledge, these results showed that more ROS generation and stronger activation of the ROS-dependent apoptotic pathway were induced by 5FU and OXA delivered by NPs. Furthermore, it was observed that NPs were hemocompatible. Co-loaded NPs exhibited significantly higher antitumor efficiency compared to free drugs combination, indicating this co-delivery system provides great potential in cancer therapy. The results of present study also confirmed that PHBV/PLGA NPs can be served as a promising platform for the co-delivery of antitumor drugs and present a new view for treatment of cancer with reducing side effect of drugs.